For instance, considering the differences in the tumor microenvironment and T-cell status of different patients and selecting the most suitable CD28-based CAR design and metabolic regulation strategies to improve therapeutic efficacy and reduce adverse effects, may offer hope for CAR-T precision therapy. Here, CD28 is linked to neoplasm.